Search results
Results from the WOW.Com Content Network
Celgene Provides REVLIMID ® Regulatory Update REVLIMID Granted Approval for Treatment of Patients with Relapsed or Refractory Multiple Myeloma in China REVLIMID ...
Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.
Don't let the headlines fool you, Celgene's (NAS: CELG) application to market Revlimid, as a maintenance treatment for newl- diagnosed multiple myeloma patients, was rejected by the EU's Committee ...
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene's Pomalyst in treating patients with multiple myeloma. Patients must have received at least two prior ...
In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Focalin XR was later launched by Celgene and Novartis in 2005.
New Jersey–based drug company Celgene (CELG) on Monday reported highly anticipated data for Revlimid, its multiple myeloma cancer pill. And it didn't disappoint: at the annual American Society ...
Oral Anti-Cancer Therapy REVLIMID ® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Treatment indicated for patients with transfusion-dependent anaemia ...